ReGum proven to treat periodontitis

Israel: ReGum, a new technology for tissue regeneration from BioChange, was found capable of treating periodontitis (gum recession disease) in canines.

The company said in a press release it could potentially help to treat 40% of adults who suffer from moderate to severe gum recession disease (periodontitis).

The Israeli startup called ReGum a “breakthrough technology for tissue regeneration”, claiming the product led to a significant regeneration of periodontal tissue (including gum and bone tissues) as compared to the standard-of-care treatment regimen.

The results were published by Dr Ana Nemec, Dr Jerzy Pawel Gawor, and Peter Strøm in Frontiers in Veterinary Science.

According to the press release, periodontal disease is very common in humans and dogs. Examining 9 dogs and 11 dog teeth pairs, the study found ReGum to be effective and safe with no side effects.

The technology is based on BioChange’s novel scaffold technology, which triggers a mechanism of repair and regeneration by the patient’s own cells. As the scaffold biologically degrades over time, it leaves behind only autologous, regenerated, healthy tissue.

At present, ReGum is commercially available for veterinary use only, although the company said it is planning to obtain regulatory approval for use in humans within the next two years.

“Periodontal disease is one of the most common oral diseases in dogs and yet there is no effective treatment option once gingivitis advances to periodontitis,” said Dr Ana Nemec, the Primary Investigator of the clinical study.

“Currently the treatment approach is mainly conservative and is based on mechanical removal of the plaque and debridement of periodontal tissues.

“With our clinical research team, we scientifically proved that the addition of the ReGum is superior to standard therapy alone in periodontal tissue repair in dogs with naturally occurring periodontitis, followed up three months after the treatment.

“The addition of this new product during the professional treatment by the vet can make a significant difference, saving more teeth from extraction.”

Said Ishay Attar, BioChange’s founder and CEO: “We are very encouraged by the results of the ReGum study.

“Dr. Nemec’s research began as an important exploration of our regenerative scaffold technology platform and eventually led to remarkable results, specifically in periodontal tissue repair.

“We were able to regenerate the complex periodontal tissue, which is made up of four different tissue types that support the tooth. No other product has been able to achieve such results in terms of safety and effectiveness.”

Founded in 2017, BioChange developed the CellFoam platform technology, which is used in stimulating the regeneration of a variety of tissues and organs. Based on this technology, BioChange built a pipeline of regenerative products.

The company’s vision is to restore body functions and tissues lost with age and degeneration.